 AbCellera Biologics Inc NASDAQ: ABCL has announced agreements to expand its collaboration with Gilead Sciences Inc NASDAQ: GILD, including a multi-year, multi-target antibody discovery collaboration. Under the agreements financial terms, AbCellera will receive an upfront payment and is eligible for milestone payments and royalties. 